Terbinafine Hydrochloride
Product Images NDC 68151-1327

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Terbinafine Hydrochloride (NDC 68151-1327). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Carilion Materials Management, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

3a183255-figure-01 (3a183255 Figure 01)

This appears to be a table or chart presenting the adverse events and discontinuations associated with the use of Lamisit Placebo. The table lists the percentage of occurrences of different symptoms such as headache, gastrointestinal symptoms (diarrhea, dyspepsia, abdominal pain, nausea, and flatulence), dermatological symptoms (rash, pruritus, and urticaria), and abnormalities in liver enzymes and taste and visual disturbances. There is a note at the end of the text mentioning that there were liver enzyme abnormalities that were 22 times the upper limit of the normal range.*

FDA Label Image

3a183255-figure-02 (3a183255 Figure 02)

FDA Label Image

3a183255-figure-03 (3a183255 Figure 03)

This appears to be a list of various symptoms that someone may be experiencing. These symptoms include nausea, stomach (abdominal) pain, rash, headache, vomiting, dizziness, and frequent urination. It's difficult to determine the underlying cause of these symptoms without additional information or context.*

FDA Label Image

3a183255-figure-04 (3a183255 Figure 04)

This appears to be a list of symptoms related to digestive and liver problems, including nausea, poor appetite, tiredness, vomiting, upper right abdominal pain, jaundice (yellowing of the skin or eyes), dark urine, and pale or light colored stools. It is important to seek medical attention for these symptoms as they could indicate a serious underlying condition.*

FDA Label Image

Label Image (68151 1327)

This is a description of a medicine called Terbinafine that comes in a tablet form of 260 mg. The medicine is manufactured by a company named 1MFG! 1rvaGan and has a code LOTH 11306267. The medicine expires on September 2014. The code Ue31714im2 and POM: 1327 are also mentioned. The quantity of the package is noted as QLT 6000001327.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.